Published in AIDS on May 28, 1999
N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med (2007) 2.41
Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med (2006) 1.85
Relationship of injection drug use, antiretroviral therapy resistance, and genetic diversity in the HIV-1 pol gene. J Acquir Immune Defic Syndr (2009) 0.76
Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS (1997) 9.08
The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA (2000) 7.65
Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA (2001) 7.63
Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA (1998) 6.69
Barriers to use of free antiretroviral therapy in injection drug users. JAMA (1998) 6.67
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 6.49
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA (1997) 6.35
The psychological consequences of predictive testing for Huntington's disease. Canadian Collaborative Study of Predictive Testing. N Engl J Med (1992) 5.51
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA (1996) 5.29
Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science (1995) 4.98
Unsafe injection practices in a cohort of injection drug users in Vancouver: could safer injecting rooms help? CMAJ (2001) 4.96
Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med (2000) 4.83
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA (1998) 4.61
Infectivity, transmission, and pathology of human-isolated H7N9 influenza virus in ferrets and pigs. Science (2013) 4.17
Preliminary evaluation of a scheme for grading the gross morphology of the human intervertebral disc. Spine (Phila Pa 1976) (1990) 4.11
HIV-1 and the aetiology of AIDS. Lancet (1993) 3.69
Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS (2001) 3.56
Prevalence and structural correlates of gender based violence among a prospective cohort of female sex workers. BMJ (2009) 3.56
Hospital utilization and costs in a cohort of injection drug users. CMAJ (2001) 3.48
The social epidemiology of human immunodeficiency virus/acquired immunodeficiency syndrome. Epidemiol Rev (2004) 3.41
Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ (1999) 3.35
Co-activation of RanGTPase and inhibition of GTP dissociation by Ran-GTP binding protein RanBP1. EMBO J (1995) 3.27
Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. Canadian Zidovudine Multi-Centre Study Group. AIDS (1989) 3.19
Decline in deaths from AIDS due to new antiretrovirals. Lancet (1997) 3.13
Do needle exchange programmes increase the spread of HIV among injection drug users?: an investigation of the Vancouver outbreak. AIDS (1999) 3.01
Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr (2000) 2.94
Practice patterns of family physicians with 2-year residency v. 1-year internship training: do both roads lead to Rome? CMAJ (1989) 2.87
Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS) Ann Intern Med (1990) 2.85
Impact of HIV infection on mortality in a cohort of injection drug users. J Acquir Immune Defic Syndr (2001) 2.80
Changes in sexual behaviour and fear of AIDS. Lancet (1984) 2.76
Factors associated with adolescent initiation of injection drug use. Public Health Rep (2001) 2.73
A reality check: the cost of making post-exposure prophylaxis available to gay and bisexual men at high sexual risk. AIDS (2000) 2.71
Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr (2001) 2.51
Lower socioeconomic status and shorter survival following HIV infection. Lancet (1994) 2.47
Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. CMAJ (2001) 2.47
Industry-sponsored clinical research: a double-edged sword. Lancet (2001) 2.45
HTLV-III infection in Canada in 1985. CMAJ (1986) 2.44
Extent to which low-level use of antiretroviral treatment could curb the AIDS epidemic in sub-Saharan Africa. Lancet (2000) 2.42
The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs. Clin Infect Dis (1998) 2.31
Spinal bone loss and ovulatory disturbances. N Engl J Med (1990) 2.31
Blood pressure screening, management and control in England: results from the health survey for England 1994. J Hypertens (1998) 2.28
Deportation along the U.S.-Mexico border: its relation to drug use patterns and accessing care. J Immigr Minor Health (2008) 2.24
Rectal gonorrhoea as an independent risk factor for HIV infection in a cohort of homosexual men. Genitourin Med (1995) 2.22
An anonymous seroprevalence survey of HIV infection among pregnant women in British Columbia and the Yukon Territory. CMAJ (1990) 2.21
Retinopathy of prematurity-induced blindness: birth weight-specific survival and the new epidemic. Pediatrics (1990) 2.18
Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. AIDS (2001) 2.15
The Vancouver Lymphadenopathy-AIDS Study: 4. Effects of exposure factors, cofactors and HTLV-III seropositivity on number of helper T cells. Can Med Assoc J (1985) 2.11
cDNA structure, tissue distribution, and chromosomal localization of rat PC7, a novel mammalian proprotein convertase closest to yeast kexin-like proteinases. Proc Natl Acad Sci U S A (1996) 2.10
The role of secondary vaccine failures in measles outbreaks. Am J Public Health (1989) 2.10
Stability of dried blood spot specimens for detection of human immunodeficiency virus DNA by polymerase chain reaction. J Clin Microbiol (1992) 2.10
Decreasing frequency but worsening mortality of acute respiratory failure secondary to AIDS-related Pneumocystis carinii pneumonia. Chest (1994) 2.10
Social determinants predict needle-sharing behaviour among injection drug users in Vancouver, Canada. Addiction (1997) 2.06
Use of dried blood spot specimens in the detection of human immunodeficiency virus type 1 by the polymerase chain reaction. J Clin Microbiol (1991) 2.05
Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J Virol (2001) 2.04
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS (2001) 2.03
The relationship between HAART use and sexual activity among HIV-positive women of reproductive age in Brazil, South Africa, and Uganda. AIDS Care (2008) 2.03
The Vancouver Lymphadenopathy-AIDS Study: 6. HIV seroconversion in a cohort of homosexual men. CMAJ (1986) 2.01
Triple-combination antiretroviral therapy in sub-Saharan Africa. Lancet (1997) 2.00
Determinants of sexual risk-taking among young HIV-negative gay and bisexual men. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.99
Prevalence of HIV infection in provincial prisons in British Columbia. CMAJ (1994) 1.96
A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine. J Virol (1998) 1.92